Every day at CIRM we get calls from people looking for a stem cell therapy to help them fight a life-threatening or life-altering disease or condition. One of the most common calls is about osteoarthritis, a painful condition where the cartilage that helps cushion our joints is worn away, leaving bone to rub on bone. … Continue reading CIRM Board invests in three new stem cell clinical trials targeting arthritis, cancer and deadly infections
Independent Citizens Oversight Committee
Baseball’s loss is CIRM’s gain as Stanford’s Linda Boxer is appointed to Stem Cell Agency Board
One of the things that fascinates me is finding out how people end up in the job they have, the job they love. It is rare that the direction they started out on is the one they end on. Usually, people take several different paths, some intended, some unintended, to get to where they want … Continue reading Baseball’s loss is CIRM’s gain as Stanford’s Linda Boxer is appointed to Stem Cell Agency Board
Improving process drives progress in stem cell research
Process is not a sexy word. No one gets excited thinking about improving a process. Yet behind every great idea, behind every truly effective program is someone who figured out a way to improve the process, to make that idea not just work, but work better. It’s not glamorous. Sometimes it’s not even pretty. But … Continue reading Improving process drives progress in stem cell research
Faster, better, more efficient. Challenging? That too. An update on CIRM 2.0.
Changing direction is never easy. The greater the change the greater the likelihood you’ll have to make adjustments and do some fine-tuning along the way to make sure you get it right. On January 1st of this year we made a big change, launching CIRM 2.0. Our President and CEO Dr. C. Randal Mills called … Continue reading Faster, better, more efficient. Challenging? That too. An update on CIRM 2.0.
How venture capital became a capital adventure for stem cell agency’s newest Board member
There’s something fascinating about looking at the arc of a person’s career. So often we start out thinking we are going to be one thing, and over the years we move in a different direction and end up doing something else entirely. That’s certainly the case with Kathy LaPorte, the newest addition to our governing … Continue reading How venture capital became a capital adventure for stem cell agency’s newest Board member